Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Benaroya Research Institute
With
AstraZeneca
Sanofi
It is recognized that there is a subset of patients who are at high risk for progression despite aggressive treatment of localized disease at the time of detection. The critical issue is in addressing micrometastatic disease that has already developed prior to diagnosis. This study utilizes daily doses of ZD1839 and weekly docetaxel for two cycles prior to radical prostatectomy.
ZD1839 has demonstrated antiproliferative activity against human tumor xenografts and in coadministration with cytotoxic agents against prostate cell lines (PC-3 and TSU-PRI). The combination of ZD1839 and docetaxel has been reported to be feasible with an acceptable toxicity profile.
This phase II, single center trial is specifically targeting those patients with high-risk adenosarcoma of the prostate.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
prostate carcinoma: clinical stage T2b-3 or serum PSA\>20 ng/ml or Gleason sum score 8-10.
ECOG performance status of 0, 1 or 2
adequate hematological, liver and renal function
existing peripheral neuropathy \< grade 1
ability to tolerate oral medications.
You may not be if
Concurrent or prior treatment with radiation, cytotoxic, biologic therapy for prostate cancer
any major surgery within four weeks
prior hormonal therapy (except finasteride for obstructive voiding symptoms- -evidence of metastatic disease, confirmed by physical examination, computed tomography of the abdomen and pelvis within 45 days and by bone scan within 60 days of signing informed consent
